Coudrain v. Walgreen Co.

2026 IL App (1st) 250614-U

• Court: Appellate Court of Illinois
• Decided: February 20, 2026
• Docket: 1-25-0614
• Status: Unpublished

Opinion

2026 IL App (1st) 250614-U FIFTH DIVISION February 20, 2026

No. 1-25-0614

NOTICE: This order was filed under Supreme Court Rule 23 and is not precedent except in the limited circumstances allowed under Rule 23(e)(1). ______________________________________________________________________________

IN THE APPELLATE COURT OF ILLINOIS FIRST DISTRICT ______________________________________________________________________________

MARILYN COUDRAIN, as Administrator of the Estate of Ellen ) Smith, et al., ) ) Plaintiff-Appellant, ) ) Appeal from the v. ) Circuit Court of ) Cook County. WALGREEN CO.; WALGREENS BOOTS ALLIANCE, INC.; ) GLAXOSMITHKLINE, LLC; GLAXOSMITHKLINE HOLDINGS ) (AMERICAS), INC.; PFIZER, INC.; BOEHRINGER INGELHEIM ) No. 23 L 3569 PHARMACEUTICALS, INC.; BOEHRINGER INGELHEIM USA ) CORPORATION; BOEHRINGER INGELHEIM CORPORATION; ) SANOFI-AVENTIS U.S. LLC; and SANOFI US SERVICES, INC., ) Honorable ) Daniel Trevino, Defendants, ) Judge Presiding. ) (Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim ) USA Corporation; Boehringer Ingelheim Corporation; Sanofi-Aventis ) U.S. LLC; and Sanofi U.S. Services, Inc., Defendants-Appellees). )

JUSTICE MIKVA delivered the judgment of the court. Presiding Justice Mitchell and Justice Wilson concurred in the judgment.

ORDER

¶1 Held: The circuit court did not err in dismissing nonresident plaintiffs’ claims for lack of personal jurisdiction where those claims did not relate to defendants’ contacts with Illinois. No. 1-25-0614

¶2 The question before us is whether the claims of these nonresident plaintiffs, who were not

injured in Illinois, can proceed in the Illinois courts against these defendants. It is undisputed that

the medication that is alleged to have injured these plaintiffs was not manufactured in Illinois, but

plaintiffs point to the fact that defendants utilized certain third-party companies in Illinois to

repackage, inspect, and distribute products for nationwide distribution and to sell this same product

to other people in Illinois. We hold that our courts do not have jurisdiction over these claims against

these defendants for the reasons outlined below and affirm the dismissal of these claims by the

circuit court.

¶3 I. BACKGROUND

¶4 The cases in which these appeals are brought are among thousands of individual lawsuits

filed in federal and various state courts against the manufacturers and marketers of Zantac, a brand

of heartburn medication with the active ingredient of ranitidine. Between August 22, 2022, and

September 26, 2022, five lawsuits with over 300 plaintiffs residing in 39 states were filed in

Madison County, Illinois. These cases were filed against numerous defendants, some of whom

have had the claims against them dismissed or have settled.

¶5 The defendants who are parties to this appeal are Boehringer Ingelheim Pharmaceuticals,

Inc., Boehringer Ingelheim Corporation, and Boehringer Ingelheim USA Corporation

(collectively, Boehringer), and Sanofi-Aventis U.S. LLC and Sanofi US Services Inc.

(collectively, Sanofi). The plaintiffs alleged in their complaint strict product liability, failure to

warn, negligent transportation and storage, negligent misrepresentation, fraud, and breach of

express and implied warranties—all stemming from their use of Zantac, which was manufactured,

marketed, and sold by these defendants and which the plaintiffs alleged caused them cancer.

On October 25, 2022, the Illinois Supreme Court consolidated these actions with several other

2 No. 1-25-0614

Illinois cases alleging similar ranitidine-related injuries in Cook County. All multi-plaintiff actions

were administratively dismissed, and plaintiffs were instructed to refile individual complaints. This

appeal concerns 180 out-of-state plaintiffs, including the first named plaintiff, Marilyn Coudrain,

as administrator of the estate of Ellen Smith, who refiled individual actions in Cook County.

¶6 On October 25, 2023, Boehringer, Sanofi, and other defendants who are not parties to this

appeal, filed a joint motion under section 2-301 of the Code of Civil Procedure (735 ILCS 5/2-301

(West 2022)) to dismiss all non-Illinois plaintiffs’ claims for lack of general and specific

jurisdiction. Boehringer and Sanofi argued that the court had no general jurisdiction over them

because neither their headquarters nor their principal places of business were in Illinois. They

argued that they were not subject to the court’s specific jurisdiction because the plaintiffs were not

residents of Illinois, had not purchased or consumed Zantac in Illinois, and were not injured in

Illinois.

¶7 After jurisdictional discovery, plaintiffs filed their response on January 10, 2025. They

argued that Boehringer and Sanofi “purposefully reached into Illinois with respect to the

development, marketing, and sales of their Zantac products.” The plaintiffs pointed to the fact that

Boehringer and Sanofi intentionally sought out and contracted with Walgreens and other Illinois

corporations for product sales and distribution, and that each plaintiff bought their Zantac from a

Walgreens store. The gist of their argument was that Boehringer utilized several Illinois companies

to help it “market, promote, and enter into contracts for selling Zantac to Walgreens, an Illinois

company, for sales nationally.”

¶8 The plaintiffs pointed out that Boehringer also contracted with two Illinois companies to

repackage Zantac for nationwide sales. The first company, Mechanical Servants, was based in

Melrose Park, Illinois. As part of this agreement, Boehringer would ship Zantac to Mechanical

3 No. 1-25-0614

Servants in Illinois, which would then put the medication into its final packaging with the

appropriate labels and package inserts. The agreement specifically noted that Mechanical Servants

was to include in its final packages the “FDA Drug Facts Labeling for the Products,” which,

according to plaintiffs, was defective and failed to warn consumers that Zantac contained NDMA,

a known carcinogen. The agreement also specified that Boehringer was to provide Mechanical

Servants samples of this FDA label as well as all “necessary Intellectual Property, Storage

Specifications and IP Specifications including all artwork, copy, or other material relating to the

Products,” which Mechanical Servants could not alter. Boehringer entered into an identical

repackaging agreement with Modern Aids, another Illinois corporation based in Elk Grove.

¶9 Boehringer also entered into an agreement with Rand Diversified Companies, LLC (Rand)

to provide quality assurance testing. Although Rand was headquartered in New Jersey, a

substantial part of this agreement was to be performed at its facility in Edwardsville, Illinois.

Additionally, Boehringer retained a Texas-based broker, Crossmark, Inc., to help it market and

sell Zantac, including to Walgreens, for nationwide sales.

¶ 10 According to plaintiffs, Sanofi earned $465,486,873.15 in revenue from the products it sold

in Illinois between 2017 and 2023. This figure included $14,652,126.54 worth of Zantac sold to

Illinois companies, nearly $5,000,000 of which was sold and shipped to Walgreens in Illinois for

national distribution. Like Boehringer, Sanofi also had agreements with Modern Aids and

Mechanical Servants to provide repackaging services in Illinois. Additionally, Sanofi contracted

with other companies with ties to Illinois to help it sell Zantac. For example, Sanofi contracted

with AmerisourceBergen to sell its products. Although AmerisourceBergen is based in Orlando,

Florida, its largest shareholder is Walgreens. Through AmerisourceBergen, Sanofi sold millions

of dollars of Zantac to retailers and distribution hubs in Illinois for Amazon, Sam’s Club,

4 No. 1-25-0614

Supervalu, McKesson, Costco, and Walgreens. The plaintiffs highlighted the fact that their failure-

to-warn claim stemmed from the defective label that did not warn consumers that Zantac contained

a known carcinogen and that that label was inserted into Zantac packages in Illinois.

¶ 11 Plaintiffs also argued that the court had general jurisdiction over Boehringer and Sanofi

under Mallory v. Norfolk Southern Railway Co., 600 U.S. 122 (2023), because some of the entities

were, or had recently been, foreign corporations registered to do business in Illinois. Plaintiffs

contended that it would be reasonable to exercise personal jurisdiction over these defendants

because similar claims of Illinois residents were continuing in Cook County, rendering the

resolution of these claims little additional burden on the state and because Illinois had significant

contacts with these companies.

¶ 12 The circuit court heard argument on January 23, 2025. The court asked the plaintiffs to

address Bristol-Myers Squibb Co. v. Superior Court, 582 U.S. 255 (2017), in which the United

States Supreme Court had held that a defendant’s relationship with a third party, standing alone,

is an insufficient basis for jurisdiction. The plaintiffs argued that unlike in that case, where sales

agents had broad discretion over where and how they sold medication, Boehringer and Sanofi

specifically directed these third parties to sell Zantac to Walgreens. In rebuttal, Boehringer and

Sanofi stressed that Bristol-Myers should control, and pointed out that the purportedly defective

labels were not drafted or created in Illinois and no plaintiff could definitively trace their pills as

having passed through Illinois.

¶ 13 The court granted Boehringer and Sanofi’s motion to dismiss. It reasoned that the

nonresident plaintiffs’ claims did not arise out of or relate to any of Boehringer or Sanofi’s

activities in Illinois and that their contacts with third-party companies to distribute, market, and

package Zantac were not a sufficient basis for jurisdiction.

5 No. 1-25-0614

¶ 14 This appeal followed.

¶ 15 II. JURISDICTION

¶ 16 The circuit court granted Boehringer and Sanofi’s motion to dismiss for lack of personal

jurisdiction in orders entered between March 5, 2025, and March 24, 2025, in the nonresident

plaintiffs’ cases, and plaintiffs timely filed a notice of appeal on April 3, 2025. We have

jurisdiction under Illinois Supreme Court Rule 301 (eff. Feb. 1, 1994) and Rule 303 (eff. July 1,

2017), which govern appeals from final judgments entered by the circuit court in civil cases.

¶ 17 III. ANALYSIS

¶ 18 The Illinois long-arm statute governs the exercise of personal jurisdiction by an Illinois

court over a nonresident defendant. 735 ILCS 5/2-209 (West 2022); Russell v. SNFA, 2013 IL

113909, ¶ 29. The statute permits the exercise of personal jurisdiction over a nonresident defendant

to the extent that it is permitted by the Illinois Constitution and the Constitution of the United

States. Russell, 2013 IL 113909, ¶ 29. Since the Illinois long-arm statute is co-extensive with the

limits of due process, we must determine whether due process permits the exercise of personal

jurisdiction over these defendants on the claims of these out-of-state plaintiffs. Id. ¶ 30.

¶ 19 Due process requires that a defendant have such “contacts” with the forum State that “the

maintenance of the suit” is “reasonable, in the context of our federal system of government,” and

“does not offend traditional notions of fair play and substantial justice.” Ford Motor Company v.

Montana Eighth Judicial District Court, 592 U.S. 351, 358 (2021). In Illinois, the “threshold issue”

is often referred to as “the ‘minimum contacts’ test.” Russell, 2013 IL 113909, ¶ 36. The contacts

necessary to satisfy this test will depend on whether the plaintiff is asserting that the court has

general or specific personal jurisdiction over a defendant. Rios, 2020 IL 125020, ¶ 19. Plaintiffs

here assert that the court had both general and specific jurisdiction over Boehringer and Sanofi.

6 No. 1-25-0614

¶ 20 General jurisdiction exists where a corporate defendant “has engaged in continuous and

substantial business activity within the forum,” and allows them to be sued for any claim,

regardless of where the conduct took place, because they are essentially “at home” in the forum

state. Id. Specific jurisdiction, on the other hand, requires a showing that (1) “the defendant

purposefully directed its activities at the forum state” and (2) “the cause of action arose out of or

relates to the defendant’s contacts with the forum state.” Russell, 2013 IL 113909, ¶ 40. Even

where these first two criteria are met, specific jurisdiction also includes a “reasonableness” prong.

Rios, 2020 IL 125020, ¶ 30.

¶ 21 It was the plaintiffs’ burden to “establish a prima facie basis for exercising personal

jurisdiction over a nonresident defendant.” Rios v. Bayer Corp., 2020 IL 125020, ¶ 16. When, as

here, the circuit court based its determination of jurisdiction solely on documentary evidence, our

review is de novo. Id. We consider plaintiffs’ claims for specific and then for general jurisdiction

over these defendants on these claims.

¶ 22 A. Specific Jurisdiction

¶ 23 Plaintiffs point out that, to satisfy the first requirement of specific jurisdiction, they only

need show that Boehringer and Sanofi purposely directed activities into Illinois and that this is not

an exacting standard. Kothawala v. Whole Leaf, LLC, 2023 IL App (1st) 210972, ¶ 29. These

activities “need not be causally or even indirectly related to the claims plaintiff raises in the lawsuit;

that deeper dive into the facts of the lawsuit occurs in the second prong regarding causation or

relatedness.” Id. Boehringer and Sanofi sold millions of dollars of Zantac in Illinois. Both also

utilized Illinois companies to market and repackage Zantac for nationwide distribution as well as

to perform quality assurance work, functions which were all, at least partially performed at various

locations throughout Illinois. Thus, it appears that defendants did direct activities into Illinois.

7 No. 1-25-0614

¶ 24 Plaintiffs also spend a great deal of their briefs discussing the reasonableness requirement.

They rely on the fact that defendants engaged in direct-to-consumer marketing efforts through a

major distributor, Walgreens, an Illinois company, and that defective and insufficient labeling took

place in Illinois. All of this, according to plaintiffs, makes it “reasonable for this Court to exercise

personal jurisdiction over the Defendants” in this case.

¶ 25 However, even if we agree that plaintiffs meet the first prong, and that the exercise of

jurisdiction would be reasonable, plaintiffs clearly fail to meet the second prong of the test for

specific personal jurisdiction, which requires that the cause of action “arose out of or relates to”

Boehringer and Sanofi’s contacts with Illinois.

¶ 26 Plaintiffs argue that their claims “relate to” Boehringer and Sanofi’s activities in Illinois

because “those activities were intentionally directed into Illinois for the purpose of getting

consumers in every state, like Plaintiffs, to believe their claims and buy their Zantac at their local

Walgreens.” Plaintiffs point to the facts cited above in their reasonableness argument regarding

nationwide marketing and repackaging in Illinois and to their allegation that each of these out-of-

state plaintiffs purchased their Zantac at a Walgreens.

¶ 27 According to plaintiffs, the circuit court misconstrued the meaning of “relate to,” a

requirement that they insist “is flexible, lenient, and does not require a showing of causation.”

Plaintiffs contend that the circuit court improperly relied on Rios and Bristol-Myers and that the

reach of these cases must be reconsidered in light of the more expansive understanding of specific

personal jurisdiction articulated by the United States Supreme Court in Ford Motor Company v.

Montana Eighth Judicial District Court, 592 U.S. 351 (2021).

¶ 28 Plaintiffs’ reliance on the analysis in Ford is misplaced. That analysis did not

fundamentally change the requirements for specific personal jurisdiction in the way plaintiffs

8 No. 1-25-0614

suggest. That case does not address cases where, as here, the plaintiffs are not residents of the

forum state and the injury did not occur in that state. The jurisdictional limitations set forth in

Bristol-Myers and Rios for claims brought by nonresident plaintiffs who suffered an injury outside

the state remain in place and are directly applicable to the facts of this case.

¶ 29 In Ford, the U.S. Supreme Court concluded that two different states could exercise

personal jurisdiction over Ford Motor Company where, in each instance, a resident of that state

was injured in that state by an allegedly defective Ford vehicle. Id. at 354-55. The two specific

vehicles at issue were not actually sold to the plaintiffs by Ford in the forum states. Id. at 355.

Rather, they were resold to the plaintiffs in those states by the prior owners. Id. at 357. The

Supreme Court rejected Ford’s argument that the courts could not exercise personal jurisdiction

over it, as a nonresident defendant, unless the company had designed, manufactured, or sold the

car in the forum state. Ford’s argument, which the Supreme Court rejected, was that the conduct

of Ford in the forum state must be what “gave rise to the plaintiff’s claims.” Id. at 361. The court

read its prior precedent as not requiring a “strict causal relationship” between a defendant’s in-

state activities and the plaintiff’s injury. Id. at 362. Rather, the plaintiff’s suit must “arise out of or

relate to the defendant’s contacts with the forum.” (Emphasis in original.) Id. (quoting Bristol-

Myers Squibb Co., 582 U.S. 255, 262 (2017)). In Ford the court found this relationship in the fact

that the car accidents took place in the forum states, the defective Ford vehicles caused the crashes

and resulting harm in the forum states, and Ford had advertised, sold, and serviced those two car

models in the forum states for many years. Id. at 365. As the court concluded, ”Ford had

systematically served a market in [the forum states] for the very vehicles that the plaintiffs allege

malfunctioned and injured them in those States.” Id.

¶ 30 Plaintiffs argue that Ford’s relaxation of the causal requirement means that they need only

9 No. 1-25-0614

show that defendants marketed and sold other units of Zantac in Illinois and utilized Illinois as part

of their nationwide distribution efforts. Their claim is that this fact and the defendants’ other

activities involving Illinois companies, like repackaging and quality assurance, are sufficient to

vest Illinois courts with jurisdiction over these defendants for claims involving nonresident

plaintiffs and injuries.

¶ 31 Plaintiffs’ argument significantly overstates the holding in Ford. Citing to Bristol-Myers,

the court in Ford explained, “That does not mean anything goes. In the sphere of specific

jurisdiction, the phrase ‘relate to’ incorporates real limits, as it must to adequately protect

defendants foreign to a forum.” Id. at 362. In Ford the necessary relationship between the injury

and the forum states was present because the plaintiffs were residents of the forum states, the

accidents that injured them took place in the forum states, and Ford had systematically served a

market for those vehicles in those states. Id. at 365. While Ford relaxed the necessary causal

relationship between defendant’s conduct in the forum state for those cases in which a claim is

brought by a resident of the forum state for an injury that occurred in that state, nothing in that

case suggests that the Court was announcing a new rule for cases like this one where there is no

tie to the forum state by way of the plaintiff’s residency or the alleged injury. Id. at 365-67.

¶ 32 Bristol-Myers and Rios, relied on by the circuit court, are both applicable here, and the

analysis of the court in each of those cases is not impacted by Ford. In Bristol-Myers, the plaintiffs

sued a pharmaceutical manufacturer in California for injuries allegedly caused by one of its

prescription drugs, Plavix. Bristol-Myers Squibb Co., 582 U.S. 255, 260 (2017). The plaintiffs

were not residents of, injured in, or treated in California and the drug was not purchased there. Id.

Plaintiffs argued that the company’s “wide ranging” business activities in the state, which included

a distribution agreement with a California company and sales in the state that led to similar claims

10 No. 1-25-0614

by residents, were enough connection to the forum state. Id. at 255. The Supreme Court explained

that these activities were insufficient to establish specific personal jurisdiction:

“[A] defendant’s relationship with a ... third party, standing alone, is an insufficient basis

for jurisdiction. This remains true even when third parties (here, the plaintiffs who reside

in California) can bring claims similar to those brought by the nonresidents. *** What is

needed—and what is missing here—is a connection between the forum and the specific

claims at issue.” Id. at 265. (Internal citations and quotation marks omitted).

¶ 33 Similarly, in Rios, nonresident plaintiffs brought an action in Illinois against an out-of-state

company for injuries suffered outside of Illinois caused by a device manufactured outside of

Illinois. Rios, 2020 IL 125020, ¶ 1. The company, Bayer, had conducted clinical trials in Illinois

(and other states), held a physician training program for the harmful device in Illinois, and

coordinated a marketing strategy in Illinois, all of which the Illinois Supreme Court found did not

sufficiently relate to the claims brought by the plaintiffs. Id. ¶ 24. Most relevant here was the

failure-to-warn allegation against Bayer, which the supreme court noted failed because “plaintiffs

fail[ed] to allege that either they or their physicians received that false information in Illinois, and

as noted, th[o]se plaintiffs and their physicians d[id] not reside in th[e] forum.” Id. ¶ 26. In short,

“nothing in their complaints link[ed] Bayer’s alleged failure to warn the nonresidents and their

physicians to any activities that occurred or should have occurred in Illinois.” Id.

¶ 34 Plaintiffs attempt to distinguish Rios on the basis that Boehringer and Sanofi utilized

Illinois companies to repackage Zantac with defective warning labels. However, as defendants

point out, there was no evidence that any of these out-of-state plaintiffs purchased a Zantac product

packaged or distributed by those Illinois companies or that there was any connection between the

conduct of these Illinois companies and the injury to these nonresident plaintiffs.

11 No. 1-25-0614

¶ 35 Plaintiffs attempt to distinguish Bristol-Myers by arguing that Boehringer and Sanofi

“reached into Illinois to create a marketing, distribution, and sales plan with Walgreens, the largest

retail pharmacy in the United States,” and that plaintiffs allege in their complaints that they

purchased their Zantac from a Walgreens store. Plaintiffs contrast these facts with those in Bristol-

Myers, where the third-party distributor was a resident of the forum state but, as the Court noted,

could not necessarily be proven to be the distributor to the pharmacies where the nonresident

plaintiffs purchased Plavix. Bristol-Myers Squibb Co., 582 U.S. 255, 268 (2017).

¶ 36 However, this distinction is not significant. Walgreens is still a third party, and the fact that

Illinois courts could have jurisdiction over a claim against them does not give rise to derivative

jurisdiction over the defendants in this case. As the court made clear in Bristol-Myers, the plaintiffs

must have jurisdiction over each of the defendants and a relationship between a defendant and a

third party, over whom the court could exercise jurisdiction, is simply not sufficient. Id. at 268.

¶ 37 B. General Jurisdiction

¶ 38 Plaintiffs also argue that Illinois can exercise general jurisdiction. They contend this

jurisdiction exists over Boehringer because it is registered to do business in Illinois and over

Sanofi because one of its companies was registered to do business in Illinois from 2006 until 2017.

¶ 39 General jurisdiction is “all-purpose” and allows the defendant to be sued for any claim,

regardless of where the plaintiff was injured or resides or where the conduct took place, because

the defendant is essentially “at home” in the forum state. Aspen American Insurance Co. v.

Interstate Warehousing, Inc., 2017 IL 121281, ¶ 14. Plaintiffs claim that Boehringer and Sanofi

should be subject to general jurisdiction “based on their foreign corporate registration under 735

ILCS 5/2-209 and the U.S. Supreme Court’s holding in Mallory.”

¶ 40 Mallory answered the narrow question of whether the federal due process clause prohibits

12 No. 1-25-0614

a State from requiring an out-of-state corporation to consent to personal jurisdiction to do business

there. Mallory, 600 U.S. at 127. The defendant corporation in that case had registered to do

business in Pennsylvania for over 20 years and understood that, pursuant to Pennsylvania law, it

would be amenable to suit there on any claim. Id. at 135. The court found that these facts and

Pennsylvania law—which it noted “is explicit that qualification as a foreign corporation shall

permit state courts to exercise general personal jurisdiction over a registered foreign

corporation”—made the exercise of general jurisdiction permissible. (Internal quotation marks

omitted.) Id. at 134. The court specifically noted that this holding was limited, explaining, “To

decide this case, we need not speculate whether any other statutory scheme and set of facts would

suffice to establish consent to suit.” Id. at 135.

¶ 41 Plaintiffs overstate the impact of Mallory, which in no way undermined the clear

pronouncement of our own supreme court in Aspen that: ‘[T]he fact that a foreign corporation has

registered to do business under the Act does not mean that the corporation has thereby consented

to general jurisdiction” of the Illinois courts. Aspen, 2017 IL 121281, ¶ 22. As our supreme court

recognized in Aspen, neither the Illinois long-arm statute (735 ILCS 5/2-209 (West 2012)) nor the

Business Corporation Act (805 ILCS 5/1.01 et seq. (West 2012)) have any provision, like the

Pennsylvania provision at issue in Mallory, that would support a claim that by registering to do

business, an out-of-state corporation consents to general personal jurisdiction. While Aspen

predates Mallory, the analysis of our supreme court regarding the relevant Illinois statutes makes

it clear that the rule in Pennsylvania simply has no application in Illinois. See Franco v. Chobani,

LLC, 789 F. Supp. 3d 584, 602 (N.D. Ill. 2025) (“Nothing in Mallory demands a different result

or upsets this [Aspen] conclusion, which is based squarely on statutory interpretation.”)

¶ 42 IV. CONCLUSION

13 No. 1-25-0614

¶ 43 The circuit court did not err in granting Boehringer and Sanofi’s motion to dismiss the

nonresident plaintiffs’ claims, where no specific or general personal jurisdiction exists. We affirm

the circuit court’s dismissal.

¶ 44 Affirmed.

¶ 45 V. APPENDIX

¶ 46 Plaintiffs-Appellants

Plaintiff Cook County Circuit Court Case Number

Ellen Smith (LEAD CASE) 2023L003569 Olivia Adams 2023L003324 Deanna Adelman 2023L004069 Anthony Anderson 2023L003624 Susan Austin 2023L003631 Janardanan Ayyappan 2023L003327 Cynthia Ballou 2023L003653 Rita Banks (for Estate of Wilbert Banks) 2023L003659 Shirley Barney 2023L003341 Venissa Barquet 2023L003675 Mary Barrett 2023L003425 Linwood Battle 2023L003673 Norene Beard 2023L003431 Jimetta Beasley 2023L003426 Barbara Belcher 2023L003430 Mary Betts 2023L003684 Michael Borookhim 2023L003957 Anthony Bouchard 2023L003697 Sybil Bouse 2023L004044 Anna Brandtjen (Estate of Anthony Brandtjen) 2023L004013 Douglas Brenton 2023L003961 Janet Brett 2023L003730 Sandra Brogan 2023L003438 Elvira Brown 2023L003735 Erin Brown 2023L004043 Shelley Bullock 2023L003463 Owen Burdge 2023L004039 Jimmy Burnside 2023L003761 Boyd Cain 2023L003700 Charles Caldwell 2023L004046 Matt Callahan 2023L003762

14 No. 1-25-0614

Alfredo Canizalez 2023L003766 Serenia Carnegie 2023L004048 Nancy Carnes (Estate of Mark Carnes) 2023L004094 Missouri Carstaffney 2023L003767 Allen Carter 2023L003667 Norma Cetuk 2023L003768 Helen Chow 2023L003704 Richard Christoffersen 2023L003988 Nicole Christopher 2023L003707 John Clare 2023L004104 Dorothy Collins 2023L003791 Gerald Combs 2023L004050 Eddie Cooper 2023L004054 Marilyn Coudrain 2023L003569 Carolyn Coughlin 2023L003712 Cynthia Covington 2023L003433 Candace Crone 2023L003785 Patricia Crouch 2023L004012 Christine Currie 2023L003432 Anthny Czerwein 2023L003440 Daisy Damian 2023L003779 Gemayel Davis 2023L003789 Michael Davis 2023L004015 Roncindra Davis 2023L003797 Jeffrey Todd Davis 2023L003795 Heidi DeClue 2023L003970 Sharmayne Dicks 2023L003787 Deborah Dodd 2023L003807 Ruth Dorrance 2023L003815 Deborah Drew 2023L003442 Nanci Drury 2023L003444 Richard Dusch 2023L003817 Roland Eaglin 2023L003820 Gary D. Eckrich 2023L003819 Cathy Evans 2023L003842 Jeanette Evans 2023L003847 Georgia Ezeilo 2023L003434 Pearl R. Fields 2023L003443 William Fleming 2023L004011 George Flint 2023L003454 Robert Florkey 2023L003845 Aaron J. Foster 2023L004093 Dennis Fox 2023L003680 Emilio Franco 2023L003848

15 No. 1-25-0614

Katrina Frazier 2023L003852 Ronald Fulmer 2023L003854 Richard Gaiti 2023L004097 Dinah George 2023L003879 Larry German 2023L004102 Jeffrey Gill 2023L003455 Khaliefe Glover 2023L003763 Emmanuel Goldstein 2023L003467 Greg Gover 2023L003738 Michael Hall 2023L003865 Shayne (Shane) M. Hall 2023L003868 Lashonda Hampton 2023L003858 Minnie Harris 2023L003871 Douglas Harrison 2023L003869 Joshua Hawkins 2023L003873 Tina Herrin 2023L003874 Tomasa Hill 2023L003876 Lois Hinkle 2023L003464 Sandra Holmes 2023L003739 Willie Holmes 2023L003731 John Holstein 2023L003465 Dawn Hurr 2023L003447 Earl Johnson 2023L003466 Lisha Johnson 2023L003467 Maria Johnson 2023L003469 Gary Johnston 2023L003470 Gilbert Joines 2023L003705 Kenya Knezevich 2023L003733 Joan Knoph 2023L003890 Leonard J. Lee 2023L003908 Carol Lorenz 2023L004100 Betty Lu bar 2023L004061 Lawrence Luckey 2023L003905 David William Lundblom 2023L003907 Carlos Maldonado 2023L003923 David Mann 2023L003504 Vicki McCall 2023L003930 David McClelland 2023L003932 Jean McDonnell 2023L003523 Curtis McPherson 2023L003744 Mark Meyer 2023L003529 Micheal Miller 2023L003920 Richard B. Moffitt 2023L004062 Kerrie L. Moran. 2023L003919

16 No. 1-25-0614

Deborah Morgan 2023L004066 Freedom Murray 2023L003915 Azmi Mustafa 2023L004005 Garard Naff 2023L003974 Albert Nevarez, Jr. 2023L004004 Robert Newman 2023L004077 Marilyn Denise Oreoluwa 2023L004127 Joshua Owens 2023L003533 Gloria Y. Pacley 2023L003535 Shanna Palmour 2023L003996 Dina Peller 2023L003750 Renita Perez 2023L004090 Kaysandra Peyton 2023L003769 Michele Dawn Piacquadio 2023L003538 Franco Polizzi 2023L003992 Marlon Pucket 2023L003984 Vadalina Quinones 2023L003542 David Long Quintero 2023L004107 Sharon Renfro 2023L003951 Patricia Rhem 2023L003939 Danica Riley 2023L003752 Vernon Risby 2023L003969 Craig Rodkin 2023L004001 Elvir Sabanovic 2023L003991 Marco Antonio Sandoval 2023L003976 Kimberly Sayles 2023L003941 Louise Scott 2023L003567 Sammy Shah 2023L003943 Patricia Siebert 2023L003568 Joseph T. Silva 2023L003916 Pamela Smith 2023L003812 Rebecca Smith 2023L003574 Talton Smith 2023L003575 Donna Snyder {Estate of Ronald Lee Snyder) 2023L003782 Melisa Sobota 2023L003579 Rose A. South 2023L003986 Christian Spining 2023L003813 Olivia Sutton 2023L003841 Jeffrey Tantleff 2023L003826 Johnnie Tarver 2023L004032 Tinisha Thomas 2023L003582 David Thurau 2023L003827 Shane Tomczak 2023L004086 Elizabeth Francy Torres Vieira 2023L003833

17 No. 1-25-0614

Timmy Trahan· 2023L003583 Courtney Turner 2023L003830 Detlef Vance 2023L004110 Tina Ayers Vick 2023L003713 Nate Vortherms 2023L003893 Kyla Voss 2023L003990 Cynthia M. Ward 2023L003882 Christopher Warren 2023L003664 Karleythia Washington 2023L003793 Stephen Weidenhamer 2023L004106 Mary Jane White 2023L003584 Kazuko Williams 2023L004052 Paul Williams 2023L003586 Quincy Carl Williams 2023L003834 Rory Williams 2023L003587 Myisha Wright 2023L003832 Allen Wronko 2023L003831 Robert Yasick 2023L003592 Sheila Furr 2023L003858 Daryle Peters 2023L003990 Cassandra Day 2023L003447 Danielle Barney 2023L003664 Marilyn Holland 2023L003463